Updated results from the BEGONIA phase 1b/2 trial for the cohort of patients treated with datopotamab deruxtecan plus durvalumab showed that the combination demonstrated durable tumor responses and no new safety signals in patients with previously untreated advanced or metastatic triple negative breast cancer with six months additional follow-up from the previous data cut-off.
